Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

70.40
0.0000
Post-market: 70.400.00000.00%19:30 EDT
Volume:615.74K
Turnover:43.32M
Market Cap:3.91B
PE:6.34
High:70.61
Open:70.61
Low:70.09
Close:70.40
52wk High:74.59
52wk Low:59.47
Shares:55.60M
Float Shares:55.60M
Volume Ratio:1.19
T/O Rate:1.11%
Dividend:0.81
Dividend Rate:1.15%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.40
PE(LYR):23.01

Loading ...

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Sep 21

J&J says Caplyta Phase 3 study in bipolar I met primary endpoint

TIPRANKS
·
Sep 21

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Sep 21

AbbVie, Iambic Sign Multiyear Drug Discovery Deal

MT Newswires Live
·
Sep 21

AbbVie Partners with Iambic to Accelerate AI-Driven Small-Molecule Drug Discovery

Reuters
·
Sep 21

Johnson & Johnson Says Phase 3 Trial Shows Caplyta Cuts Bipolar I Mania Symptoms by Week 3

Reuters
·
Sep 21

Abbvie and Iambic Announce Collaboration to Accelerate AI-Driven Drug Discovery

THOMSON REUTERS
·
Sep 21

Abbvie - Iambic to Receive Upfront Payment, Milestone Payments, and Tiered Royalties from Collaboration

THOMSON REUTERS
·
Sep 21

Abbvie - Partnership to Accelerate Small Molecule Drug Discovery in Immunology, Neuroscience, Oncology

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Demonstrates Statistically Significant Rapid Reduction in Manic Symptoms at Week 3

THOMSON REUTERS
·
Sep 21

Caplyta® (Lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Pivotal Phase 3 Study

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Well-Tolerated; Dry Mouth and Nausea Most Common Adverse Events

THOMSON REUTERS
·
Sep 21

Adarx Pharmaceuticals: IPO Price Expected Between $15 and $17 Per Share

Reuters
·
Sep 21

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

LIVE Markets-Big Beauty Faces Growing Threat from AI, Smaller Rivals

Reuters
·
Sep 21

ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO

Dow Jones
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Japan Health Ministry Approves Merck’s Keytruda QLEX for Subcutaneous Use Across Keytruda Indications

Reuters
·
Sep 21

Merck’s Keytruda Qlex™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph) Approved in Japan for Subcutaneous Administration for All Keytruda® (Pembrolizumab) Indications Approved in Japan

THOMSON REUTERS
·
Sep 21